BML Capital Management LLC Purchases Shares of 154,961 Janux Therapeutics, Inc. $JANX

BML Capital Management LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 154,961 shares of the company’s stock, valued at approximately $2,154,000. Janux Therapeutics makes up approximately 1.4% of BML Capital Management LLC’s investment portfolio, making the stock its 12th largest position.

Several other institutional investors and hedge funds have also recently modified their holdings of JANX. Rhenman & Partners Asset Management AB boosted its position in shares of Janux Therapeutics by 125.1% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 225,377 shares of the company’s stock valued at $3,110,000 after buying an additional 125,250 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in Janux Therapeutics in the 4th quarter valued at $536,000. Y Intercept Hong Kong Ltd purchased a new stake in Janux Therapeutics in the 1st quarter valued at $1,946,000. SG Americas Securities LLC lifted its stake in Janux Therapeutics by 175.1% during the 4th quarter. SG Americas Securities LLC now owns 79,817 shares of the company’s stock valued at $1,101,000 after acquiring an additional 50,802 shares in the last quarter. Finally, Profund Advisors LLC lifted its stake in Janux Therapeutics by 289.5% during the 4th quarter. Profund Advisors LLC now owns 64,022 shares of the company’s stock valued at $884,000 after acquiring an additional 47,584 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 1.2%

JANX stock opened at $15.84 on Friday. The stock has a market cap of $965.92 million, a P/E ratio of -8.61 and a beta of 2.52. The stock’s fifty day simple moving average is $14.62 and its two-hundred day simple moving average is $14.24. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to analysts’ expectations of $4.36 million. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Maria Dobek sold 2,038 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the transaction, the vice president owned 32,270 shares in the company, valued at approximately $457,265.90. This represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on JANX. JonesTrading reduced their target price on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. Piper Sandler dropped their price target on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Truist Financial restated a “buy” rating and set a $26.00 price target (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Wall Street Zen raised shares of Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Finally, Barclays lowered shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and decreased their price objective for the company from $29.00 to $14.00 in a research note on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.08.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.